Schnell T, Aranha G V, Sontag S J, Tode R, Reid S, Chejfec G, Karpf J, Levine G
Gastroenterology, Ambulatory and Surgical Service, Veterans Affairs, Edward Hines Jr. Hospital, Ill.
Surgery. 1994 Oct;116(4):798-802; discussion 802-3.
Recent screening studies with fecal occult blood testing (FOBT) report that one of three patients with colorectal cancer (CRC) can be cured of the disease; minimal attention has been given to the two of three patients who despite repeated screening go on to die of silent CRC. We report the known "miss rate" (known false negatives) of our 14-year ongoing program of FOBT that was organized in 1979 to detect early CRC.
From October 1979 through December 1993, 36,034 FOBT kits were distributed to patients who were without gastrointestinal complaints at Hines Veterans Affairs Hospital. The test was considered positive if at least one result of the six tests was positive and negative if the test result was equivocal. Patients with negative FOBT received a new test kit each year by mail. A positive test was followed by full colonoscopy or an air contrast barium enema if a full colonoscopy was not possible.
The overall return rate was 47.8%. CRC was detected in 115 patients: 94 had a favorable and 21 had an unfavorable Duke's C or D or lymphoma prognosis. Of 21 patients 13 (62%) had initially tested FOBT negative (missed lesion). Of the 21 cases of advanced CRC 15 (71.43%) were in the descending, sigmoid, or rectosigmoid colon or rectum.
(1) The majority (82%) of all CRC detected by FOBT screening are diagnosed at a favorable stage. (2) The majority of known advanced CRC (62%) escape early detection with FOBT. (3) Five (62.5%) of eight of the advanced CRC cases discovered on initial FOBT and 10 (76.9%) of 13 of advanced CRC cases missed on initial FOBT but detected in subsequent years were in the left colon and most likely in the range of the flexible sigmoidoscope. (4) FOBT as a sole screening test may provide a false sense of security, especially in patients with advanced left-side CRC.
近期粪便潜血试验(FOBT)筛查研究报告称,三分之一的结直肠癌(CRC)患者可治愈该疾病;而对于另外三分之二尽管接受了反复筛查仍死于无症状CRC的患者,关注甚少。我们报告了1979年启动的旨在检测早期CRC的FOBT 14年项目已知的“漏检率”(已知假阴性)。
1979年10月至1993年12月,向Hines退伍军人事务医院无胃肠道不适的患者分发了36,034套FOBT检测试剂盒。如果六项检测中至少有一项结果为阳性,则该检测被视为阳性;如果检测结果不明确,则视为阴性。FOBT检测结果为阴性的患者每年通过邮件收到一套新的检测试剂盒。检测结果为阳性后,若无法进行全结肠镜检查,则进行全结肠镜检查或气钡双重造影灌肠。
总体回收率为47.8%。115例患者检测出CRC:94例预后良好,21例杜克分期为C或D期、预后不良或为淋巴瘤。21例患者中,13例(62%)最初FOBT检测为阴性(漏检病变)。21例晚期CRC患者中,15例(71.43%)位于降结肠、乙状结肠或直肠乙状结肠交界处或直肠。
(1)通过FOBT筛查检测出的所有CRC中,大多数(82%)在预后良好的阶段被诊断出来。(2)大多数已知的晚期CRC(62%)通过FOBT未能早期检测出来。(3)最初FOBT检测发现的8例晚期CRC病例中有5例(62.5%),最初FOBT漏检但随后几年检测出的13例晚期CRC病例中有10例(76.9%)位于左半结肠,很可能在可弯曲乙状结肠镜检查范围内。(4)FOBT作为唯一的筛查检测可能会提供一种虚假的安全感,尤其是对于晚期左半结肠癌患者。